FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

McDonough John
2. Issuer Name and Ticker or Trading Symbol

T2 Biosystems, Inc. [ TTOO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

101 HARTWELL AVE
3. Date of Earliest Transaction (MM/DD/YYYY)

1/8/2020
(Street)

LEXINGTON, MA 02421
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 1/8/2020  M  16666 A (1)470285 (2)D  
Common Stock 1/8/2020  M  100000 A (1)570285 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Restricted Stock Units  (1)1/8/2020  D     326087   (3) (3)Common Stock 326087 $0.00 0 D  
Restricted Stock Units  (1)1/8/2020  M     16666   (4) (4)Common Stock 16666 $0.00 0 D  
Restricted Stock Units  (1)1/8/2020  M     100000   (4) (4)Common Stock 100000 $0.00 0 D  

Explanation of Responses:
(1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
(2) Includes 5,399 shares acquired under the Issuer's employee stock purchase plan on May 15, 2019.
(3) On March 15, 2018, the reporting person was granted Performance Restricted Stock Units that vest in the form of common stock based upon the achievement of certain pre-established 90-day average daily closing prices per share goals over a three year performance period. On January 8, 2020, the reporting person incurred a termination of service and forfeited the remaining unvested RSU's subject to this grant.
(4) Pursuant to the terms of that certain Employment Agreement by and between the reporting person and Issuer, dated March 4, 2008, as amended by that certain First Amendment to Employment Agreement, dated July 7, 2014 and that certain Second Amendment to Employment Agreement, dated July 30, 2019, upon the reporting person's resignation as Chief Executive Officer, these RSUs automatically vested on January 8, 2020.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
McDonough John
101 HARTWELL AVE
LEXINGTON, MA 02421
X



Signatures
/s/ John Sprague, Attorney-in-fact1/10/2020
**Signature of Reporting PersonDate

T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more T2 Biosystems Charts.
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more T2 Biosystems Charts.